| Proto-oncogene tyrosine-protein kinase LCK | Clinical trial target | FYN;p59-Fyn;Protooncogene Syn;SLK | Philadelphia-positive leukemia | Dasatinib;Dasatinib;VX-680;JNJ-26483327;CI-1040 | GW-788388;Lymphocyte-specific tyrosine kinase inhibitors;compound 30;PD-0173956;PD-0173952;SU 6656;ZM-336372;PD-0179483;L-779450;AG-1879;4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole;compound 2;Dasatinib;Y-c[D-Pen-(3-I)Tyr-GSFC]KR-NH2;PD-0173955;PD-0173958;WH-4-023;NM-PP1;Lck inhibitor;CGP-57380;Y-c[D-Pen-(3,5-diI)Tyr-GSFC]KR-NH2;CEP-5104;RPR-108518A;Phosphoaminophosphonic Acid-Adenylate Ester;VX-680;JNJ-28312141;JNJ-26483327;A-770041;PD-0180970;LAVENDUSTIN A;A-641359;4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine;compound 7;RO-316233;A-420983;BISINDOLYLMALEIMIDE IX;AZD-1152-HQPA;CI-1040;GF-109203;6-o-tolylquinazolin-2-amine;KN-62;BMS-536924;Lck tyrosine kinase inhibitors;(4-Phenoxy-phenyl)-quinazolin-4-yl-amine;JNJ-10198409;compound 19a;STAUROSPORINONE;PD-0166326;3-(4-(o-toluidino)pyrimidin-2-ylamino)benzamide;TG-100435;4-(3-Chloro-phenoxy)-6,7-dimethoxy-quinazoline;compound 23;2-(3,4,5-Trihydroxy-benzylidene)-malononitrile | |